Reports
Sale
Global Neurological Disease Treatment Market Size, Forecast: By Drug Type: Antiepileptic, Antipsychotic, Antidepressant, Cholinesterase Inhibitors, NMDA Receptor Antagonists, Others; By Disease Type: Alzheimer’s Disease, Others; By Route of Administration; By End Use; Regional Analysis; Competitive Landscape; 2024-2032
Global Neurological Disease Treatment Market Outlook
The global market for neurological disease treatment is expected to grow at a CAGR of about 5.7% in the forecast period of 2024-2032, owing to the increasing prevalence of neurological disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America to be a Significant Regional Market for Neurological Disease Treatment
The global market for neurological disease treatment is expected to be dominated by North America. One of the key reasons for the growth of the North American market is the increasing prevalence of neurological diseases across the region. According to the Alzheimer's Association, around 6 million people in the United States are currently living with Alzheimer's. The number of people suffering from this condition is projected to reach 13 million by 2050. An estimated 6.5 million Americans aged 65 and above will be living with Alzheimer's in 2023. Also, growing healthcare spending and the availability of a matured and well-established nature of healthcare infrastructure are expected to propel the market growth in North America. Government agencies, including the United States Food and Drug Administration, which manages central nervous system treatment regulatory guidelines, are expected to support the market's growth. Further, the launch of new treatments for treating these diseases, such as Huntington's disease, may drive the growth of the global neurological disease treatment market in the region. For instance, in December 2021, Novartis received approval from the US Food and Drug Administration (FDA) for Fast Track designation for branaplam (LMI070) for the treatment of Huntington's disease (HD).
Market Segmentations
Medically, neurological diseases are issues that affect the brain and the nerves found throughout the human body, including the spinal cord. Medicines may be administered via drug pumps, deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, and spinal surgery may be used to treat nervous system diseases or disorders.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on drug type, the neurological disease treatment market is divided into:
- Antiepileptic
- Antipsychotic
- Antidepressant
- Cholinesterase Inhibitors
- NMDA Receptor Antagonists
- Others
The various types of disease studied in the market are:
- Alzheimer’s Disease
- Cerebrovascular Disease
- Parkinson’s Disease
- Epilepsy
- Multiple Sclerosis
- Others
By route of administration, the market can be divided into:
- Oral
- Parenteral
- Others
The end-uses of the neurological disease treatment market are:
- Hospitals
- Speciality Clinics
- Homecare
- Others
The regional markets for neurological disease treatment can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Incidence of Neurological Diseases Propelling the Market Growth
The rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease, among others, are fuelling the expansion of the neurological disease treatment market. According to the National Library of Medicine, the predicted global population of people with multiple sclerosis reached 2.8 million in 2020. This rise is expected to have a significant impact on market growth in the coming years. The rising prevalence of neurological disorders and rising diagnosis rates in both developed and developing countries have resulted in a large patient pool requiring treatment. This is further assisted by non-profit organisations, healthcare institutions, and market participants focusing on raising awareness of these disorders through campaigns. These factors, together with the development of a new generation of antipsychotic medications by global and domestic market participants, are expected to fuel the market's growth potential. In addition, the rising research and development activities to find remedies for such ailments are driving the global market growth.
Key Players in the Global Market for Neurological Disease Treatment
The report gives a detailed analysis of the following key players in the global neurological disease treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- AbbVie Inc.
- Abbott Laboratories
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd
- Gilead Sciences, Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Disease Type |
|
| Breakup by Route of Administration |
|
| Breakup by End Use |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Neurological Disease Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Neurological Disease Treatment Historical Market (2018-2023)
8.3 Global Neurological Disease Treatment Market Forecast (2024-2032)
8.4 Global Neurological Disease Treatment Market by Drug Type
8.4.1 Antiepileptic
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Antipsychotic
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Antidepressant
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.4 Cholinesterase Inhibitors
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.5 NMDA Receptor Antagonists
8.4.5.1 Historical Trend (2018-2023)
8.4.5.2 Forecast Trend (2024-2032)
8.4.6 Others
8.5 Global Neurological Disease Treatment Market by Disease Type
8.5.1 Alzheimer’s Disease
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Cerebrovascular Disease
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Parkinson’s Disease
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Epilepsy
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Multiple Sclerosis
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Others
8.6 Global Neurological Disease Treatment Market by Route of Administration
8.6.1 Oral
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Parenteral
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Others
8.7 Global Neurological Disease Treatment Market by End Use
8.7.1 Hospitals
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Speciality Clinics
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Homecare
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Others
8.8 Global Neurological Disease Treatment Market by Region
8.8.1 North America
8.8.1.1 Historical Trend (2018-2023)
8.8.1.2 Forecast Trend (2024-2032)
8.8.2 Europe
8.8.2.1 Historical Trend (2018-2023)
8.8.2.2 Forecast Trend (2024-2032)
8.8.3 Asia Pacific
8.8.3.1 Historical Trend (2018-2023)
8.8.3.2 Forecast Trend (2024-2032)
8.8.4 Latin America
8.8.4.1 Historical Trend (2018-2023)
8.8.4.2 Forecast Trend (2024-2032)
8.8.5 Middle East and Africa
8.8.5.1 Historical Trend (2018-2023)
8.8.5.2 Forecast Trend (2024-2032)
9 North America Neurological Disease Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Neurological Disease Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Neurological Disease Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Neurological Disease Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Neurological Disease Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 AbbVie Inc.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Abbott Laboratories
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Merck & Co., Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 F. Hoffmann-La Roche Ltd
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Gilead Sciences, Inc.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Neurological Disease Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Neurological Disease Treatment Historical Market: Breakup by Treatment Type (USD Million), 2018-2023
3. Global Neurological Disease Treatment Market Forecast: Breakup by Treatment Type (USD Million), 2024-2032
4. Global Neurological Disease Treatment Historical Market: Breakup by Disease Type (USD Million), 2018-2023
5. Global Neurological Disease Treatment Market Forecast: Breakup by Disease Type (USD Million), 2024-2032
6. Global Neurological Disease Treatment Historical Market: Breakup by End Use (USD Million), 2018-2023
7. Global Neurological Disease Treatment Market Forecast: Breakup by End Use (USD Million), 2024-2032
8. Global Neurological Disease Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Neurological Disease Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Neurological Disease Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Neurological Disease Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Neurological Disease Treatment Market Structure.
Key Questions Answered in the Report
The market is projected to grow at a CAGR of 5.7% between 2024 and 2032.
The major drivers of the market include the growing healthcare spending, availability of a matured and well-established nature of healthcare infrastructure, launch of new treatments for treating these diseases, rising awareness of these disorders, and rising research and development activities.
The rapidly increasing prevalence and incidences of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease, and the rising diagnosis rates in both developed and developing countries are the key industry trends propelling the growth of the market.
What are the major regional markets for neurological disease treatment, according to the EMR report?
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on drug type, the market is divided into antiepileptic, antipsychotic, antidepressant, cholinesterase inhibitors, and NMDA receptor antagonists, among others.
The various types of disease studied in the market are Alzheimer’s disease, Cerebrovascular disease, Parkinson’s disease, epilepsy, and multiple sclerosis, among others.
Based on route of administration, the market includes oral and parenteral, among others.
The end-uses of the market are hospitals, speciality clinics, and homecare, among others.
The major players in the industry are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and Gilead Sciences, Inc., among others.
Analyst Review
The global neurological disease treatment market was driven by the rapidly increasing prevalence and incidence of neurological disorders, such as multiple sclerosis, Parkinson's disease, and Alzheimer's disease in the historical period. Aided by the growing healthcare spending and rising diagnosis rates in both developed and developing countries, the market is expected to grow at a CAGR of 5.7% in the forecast period of 2024-2032.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on drug type, the market is divided into antiepileptic, antipsychotic, antidepressant, cholinesterase inhibitors, and NMDA receptor antagonists, among others. The various types of disease studied in the market are Alzheimer’s disease, Cerebrovascular disease, Parkinson’s disease, epilepsy, and multiple sclerosis, among others. Based on route of administration, the market includes oral and parenteral, among others. The end-uses of the market are hospitals, speciality clinics, and homecare, among others. The major regional markets for neurological disease treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the above market are AbbVie Inc., Abbott Laboratories, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, and Gilead Sciences, Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER